|Bid||26.08 x 800|
|Ask||40.77 x 1800|
|Day's Range||25.60 - 26.25|
|52 Week Range||20.65 - 27.29|
|Beta (5Y Monthly)||2.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||1.56 (6.01%)|
|Ex-Dividend Date||May 14, 2021|
|1y Target Est||N/A|
Virtual Investor Conferences® and KCSA Strategic Communications today announced that the presentations from the September 8th & 9th Cannabis Industry Virtual lnvestor Conference are now available for on-demand viewing at VirtualInvestorConferences.com.
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it has conducted a recent experimental study of its CBD-loaded liposome technology (LPT) on large animals that demonstrated a similar pharmacokinetic profile as was demonstrated in a previous small animal study. This result is expected to bring the Company closer to clinical trials in humans.Pharma
Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The two-day program begins at 11:30 AM ET on Wednesday, September 8th.